Article Details

Chinese biopharma firm developing diabetes drugs raises $122 million in lead-up to IPO

Retrieved on: 2020-12-08 00:11:15

Tags for this article:

Click the tags to see associated articles and topics

Chinese biopharma firm developing diabetes drugs raises $122 million in lead-up to IPO. View article details on hiswai:

Excerpt

The round was led by <b>Jack Ma's</b> Yunfeng Capital, Yingke PE, and life-science-specialized TF Capital, and joined by Qianhai FoF, Zhongxin Huihai ...

Article found on: supchina.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo